The U.S. Food and Drug Administration issued 30 warning letters to telehealth and compounding firms it says are marketing unapproved, misbranded compounded GLP‑1 products as equivalent to approved brand therapies. The agency asserted that these firms made false or misleading claims about safety and efficacy and warned of potential enforcement actions, including seizure and injunction, if violations are not corrected. FDA Commissioner Marty Makary has signaled intensified oversight of compounded obesity and diabetes drugs amid surging demand; the move underscores regulatory risk for direct‑to‑consumer telehealth models that position compounded formulations as substitutes for approved biologics.